Immutep Says its Mid-Stage Trial of Eftilagimod Alfa Meets Primary Endpoint of Tumor Hyalinization/Fibrosis
MT Newswires Live
Oct 20
Immutep (IMMP) said Monday that its Eftisarc-neo mid-stage study of eftilagimod alfa with radiotherapy plus Keytruda has met its primary endpoint and "significantly exceeded" the trial's prespecified 35% tumor hyalinization/fibrosis.
The company said the trial enrolled 38 participants and found that the novel combination with eftilagimod alfa resulted in a median 51.5% tumor hyalinization/fibrosis in patients with soft tissue sarcoma.
The trial showed a "very good safety profile" for the therapy, with results obtained across multiple soft tissue sarcoma subtypes, the company said.
Shares of the company were down 1.9% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.